Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 42 | 81 | 101 | 60 | 64 | 63 | 64 | 63 |
| Operating profit | $bn | 17.4 | 15.2 | ||||||
| Net profit | $bn | 9.2 | 22.0 | 31.4 | 2.1 | 8.0 | 7.8 | 4.0 | 17.4 |
| EPS reported | $ | 1.36 | 0.70 | ||||||
| Operating cashflow per share | $ | 2.06 | 2.49 | ||||||
| Capex per share | $ | 0.46 | 0.42 | ||||||
| FCF per share | $ | 1.60 | 2.07 | ||||||
| Free cash flow | $bn | 9.1 | 11.8 | ||||||
| Net debt | $bn | 51.5 | 48.4 | ||||||
| Book value equity | $bn | 86.5 | 89.0 | ||||||
| Book value per share | $ | 15.21 | 15.48 | ||||||
| Number of shares | m | 5,686 | 5,751 | ||||||
| DPS (TTM paid) | $ | 1.72 | 1.72 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 18.31 | 42.26 | ||||||
| P/B LTM | x | 1.64 | 1.89 | ||||||
| P/S LTM | x | 2.26 | 2.64 | ||||||
| P/FCF LTM | x | 15.59 | 14.24 | ||||||
| EV/EBITDA LTM | x | 12.38 | 16.06 | ||||||
| EV/Sales LTM | x | 3.32 | 3.40 | ||||||
| Earnings Yield LTM | % | 5.46% | 2.37% | ||||||
| FCF Yield | % | 6.41% | 7.02% | ||||||
| Quality | |||||||||
| ROE | % | 8.99% | 4.60% | ||||||
| ROIC | % | 9.97% | 8.26% | ||||||
| Operating margin | % | 27.82% | 23.83% | ||||||
| Gross margin | % | 74.33% | 73.37% | ||||||
| FCF/Sales | % | 14.50% | 18.53% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -3.55% | -59.30% | ||||||
| Sales Growth YoY | % | -1.65% | +1.33% | ||||||
| Net Income Growth YoY | % | -3.24% | -58.96% | ||||||
| FCF Growth | % | -7.72% | +13.60% | ||||||
| Operating Profit Growth | % | +16.53% | -10.30% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 6.91% | 5.84% | ||||||
| Dividend Growth | % | +2.38% | 0.00% | ||||||
| Payout Ratio | % | 126.36% | 245.82% | ||||||
| FCF/Debt | x | 0.13 | 0.19 | ||||||
| Net Debt/EBITDA | x | 3.95 | 4.52 | ||||||
| EBIT/Net interest | x | 6.52 | 5.60 | ||||||
| Net debt/market cap | % | 36.42% | 28.83% | ||||||
| Net debt/Equity | x | 0.60 | 0.54 | ||||||
| Gross debt/equity | x | 0.78 | 0.70 | ||||||
ETFs that hold Pfizer
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| State Street Health Care Select Sector SPDR ETF | XLV | 10 | 2.51% |
| iShares Select Dividend ETF | DVY | 1 | 2.40% |
| Pacer US Cash Cows 100 ETF | COWZ | 6 | 2.12% |
| Vanguard Health Care ETF | VHT | 10 | 2.27% |
| VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF | VDIV.DE | 2 | 4.40% |
| iShares MSCI USA Value Factor ETF | VLUE | 6 | 1.98% |
| First Trust Morningstar Dividend Leaders Index Fund | FDL | 3 | 6.38% |
| State Street SPDR Portfolio S&P 500 High Dividend ETF | SPYD | 5 | 1.51% |
| iShares U.S. Healthcare ETF | IYH | 10 | 2.44% |
| Xtrackers MSCI World Value UCITS ETF 1C | XDEV.DE | 9 | 1.28% |
Funds with Pfizer among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| State Street Health Care Select Sector SPDR ETF | XLV | 10 | 2.51% |
| iShares Select Dividend ETF | DVY | 1 | 2.40% |
| Pacer US Cash Cows 100 ETF | COWZ | 6 | 2.12% |
| Vanguard Health Care ETF | VHT | 10 | 2.27% |
| VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF | VDIV.DE | 2 | 4.40% |
| iShares MSCI USA Value Factor ETF | VLUE | 6 | 1.98% |
| First Trust Morningstar Dividend Leaders Index Fund | FDL | 3 | 6.38% |
| State Street SPDR Portfolio S&P 500 High Dividend ETF | SPYD | 5 | 1.51% |
| iShares U.S. Healthcare ETF | IYH | 10 | 2.44% |
| Xtrackers MSCI World Value UCITS ETF 1C | XDEV.DE | 9 | 1.28% |
Funds with Pfizer among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free